(Q37815613)

23 August 2017

1 reference

title

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? (English)

1 reference

23 August 2017

0 references

1 reference

1 reference

3

0 references

Gaspare Gulotta

7

0 references

Daniele Santini

6

0 references

Viviana Bazan

8

object named as

Viviana Bazan

1 reference

23 August 2017

5

Nicola Silvestris

1 reference

23 August 2017

Sergio Rizzo

1

1 reference

23 August 2017

Giuseppe Bronte

2

1 reference

23 August 2017

Lidia Corsini

4

1 reference

23 August 2017

Nicola Gebbia

9

1 reference

23 August 2017

Fabio Fulfaro

10

1 reference

23 August 2017

Antonio Russo

11

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

Cancer Treatment Reviews

1 reference

23 August 2017

36 Suppl 3

1 reference

23 August 2017

S56-61

1 reference

Global cancer statistics, 2002

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Regional liver therapy using oncolytic virus to target hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Genetic alterations during colorectal-tumor development

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

1 reference

7 January 2021

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

The epidermal growth factor receptor as a target for gastrointestinal cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Epidermal growth factor receptor inhibition strategies in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

EGFR signaling and drug discovery.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Hyperactive Ras in developmental disorders and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

K-ras gene mutation in colorectal adenomas and carcinomas from familial adenomatous polyposis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Moyamoya disease and moyamoya syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

PTEN gene mutations in colorectal cancers displaying microsatellite instability

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970021-9

7 January 2021

10.1016/S0305-7372(10)70021-9

Identifiers

DOI

1 reference

23 August 2017

1 reference